...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neuro-Oncology >Imaging of integrin α_vβ_3 expression in patients with malignant glioma by [~(18)F] Galacto-RGD positron emission tomography
【24h】

Imaging of integrin α_vβ_3 expression in patients with malignant glioma by [~(18)F] Galacto-RGD positron emission tomography

机译：[〜（18）F] Galacto-RGD正电子发射断层显像对恶性神经胶质瘤患者整联蛋白α_vβ_3表达的成像

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inhibitors targeting the integrin α_vβ_3 are promising new agents currently tested in clinical trials for supplemental therapy of glioblastoma multiforme (GBM). The aim of our study was to evaluate ~(18)F-labeled glycosy-lated Arg-Gly-Asp peptide ([~(18)F]Galacto-RGD) PET for noninvasive imaging of α_vβ_3 expression in patients with GBM, suggesting eligibility for this kind of additional treatment. Patients with suspected or recurrent GBM were examined with [~(18)F] Galacto-RGD PET. Standardized uptake values (SUVs) of tumor hotspots, galea, and blood pool were derived by region-of-interest analysis. [~(18)F]Galacto-RGD PET images were fused with cranial MR images for image-guided surgery. Tumor samples taken from areas with intense tracer accumulation in the [~(18)F]Galacto-RGD PET images and were analyzed histo-logically and immunohistochemically for α_vβ_3 integrin expression. While normal brain tissue did not show significant tracer accumulation (mean SUV, 0.09 ± 0.04),rnGBMs demonstrated significant but heterogeneous tracer uptake, with a maximum in the highly proliferating and infiltrating areas of tumors (mean SUV, 1.6 ± 0.5). Immunohistochemical staining was prominent in tumor microvessels as well as glial tumor cells. In areas of highly proliferating glial tumor cells, tracer uptake (SUVs) in the [~(18)F]Galacto-RGD PET images correlated with immunohistochemical α_vβ_3 integrin expression of corresponding tumor samples. These data suggest that [~(18)F] Galacto-RGD PET successfully identifies α_vβ_3 expression in patients with GBM and might be a promising tool for planning and monitoring individualized cancer therapies targeting this integrin.
机译：靶向整联蛋白α_vβ_3的抑制剂是有前途的新药物，目前正在临床试验中测试多形性胶质母细胞瘤（GBM）的补充治疗。我们的研究目的是评估〜（18）F标记的糖基化Arg-Gly-Asp肽（[〜（18）F] Galacto-RGD）PET对GBM患者α_vβ_3表达的非侵入性成像，表明其合格性对于这种额外的治疗。怀疑或复发性GBM的患者接受了[〜（18）F] Galacto-RGD PET检查。通过感兴趣区域分析得出肿瘤热点，galea和血池的标准化摄取值（SUVs）。 [〜（18）F] Galacto-RGD PET图像与颅MR图像融合，用于图像引导手术。从[〜（18）F] Galacto-RGD PET图像中示踪剂富集区域采集的肿瘤样品，从组织学和免疫组化方面分析α_vβ_3整联蛋白的表达。尽管正常的脑组织没有显示出明显的示踪剂蓄积（平均SUV，0.09±0.04），但是rnGBMs却显示出显着但异质的示踪剂吸收，在肿瘤的高度增殖和浸润区域最大（平均SUV，1.6±0.5）。免疫组织化学染色在肿瘤微血管以及神经胶质瘤细胞中很明显。在高度增殖的神经胶质瘤细胞区域，[〜（18）F] Galacto-RGD PET图像中的示踪剂摄取（SUVs）与相应肿瘤样品的免疫组织化学α_vβ_3整联蛋白表达相关。这些数据表明，[〜（18）F] Galacto-RGD PET成功地鉴定了GBM患者中的α_vβ_3表达，并且可能是有针对性的计划和监测针对该整合素的个体化癌症治疗的工具。

著录项

  • 来源
    《Neuro-Oncology》 |2009年第6期|861-870|共10页
  • 作者

    Oliver Schnell; Bjarne Krebs; Janette Carlsen; Isabelle Miederer; Claudia Goetz; Roland H. Goldbrunner; Hans-Juergen Wester; Roland Haubner; Gabriele Poeepperl; Markus Holtmannspoetter; Hans A. Kretzschmar; Horst Kessler; Joerg-Christian Tonn; Markus Schwaiger; Ambros J. Beer;

  • 作者单位

    Department of Neurosurgery Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Center for Neuropathology and Priori Research Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany;

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany;

    Department of Neurosurgery Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Department of Neurosurgery Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany;

    Universitaetsklinik fuer Nuklearmedizin, Medizinische Universitaet Innsbruck, Austria;

    Department of Nuclear Medicine Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Department of Neuroradiology Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Center for Neuropathology and Priori Research Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Center of Integrated Protein Science, Department of Chemistry, Technische Universitat Munchen, Garching, Germany;

    Department of Neurosurgery Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Munich, Germany;

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany;

    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    α_vβ_3; ~(18)FGalacto-RGD; malignant glioma; PET; integrins;

    机译：α_vβ_3;[〜（18）F] Galacto-RGD;恶性神经胶质瘤宠物;整合素;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号